EP0581777A1 - Preparation stereoselective de piperidines substituees - Google Patents

Preparation stereoselective de piperidines substituees

Info

Publication number
EP0581777A1
EP0581777A1 EP92905084A EP92905084A EP0581777A1 EP 0581777 A1 EP0581777 A1 EP 0581777A1 EP 92905084 A EP92905084 A EP 92905084A EP 92905084 A EP92905084 A EP 92905084A EP 0581777 A1 EP0581777 A1 EP 0581777A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
process according
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP92905084A
Other languages
German (de)
English (en)
Inventor
Terry Jay Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP0581777A1 publication Critical patent/EP0581777A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
    • C07C45/513—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being an etherified hydroxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to novel processes for th stereoselective preparation of substituted piperidin derivatives.
  • the substituted piperidines and related compounds tha can be prepared by the processes of this invention ar substance P receptor antagonists and are therefore useful i treating diseases mediated by an excess of substance P.
  • Substance P is a naturally occurring undecapeptid belonging to the tachykinin family of peptides, the latte being named for their prompt stimulatory action on smoot muscle tissue. More specifically, substance P is a phar ⁇ macologically-active neuropeptide that is produced i mammals (having originally been isolated from gut) an possesses a characteristic amino acid sequence that is illustrated by D.F. Veber et al. in U.S. Patent No. 4,680,283.
  • substance P has been shown to be involved in the transmission of pain or migraine (see B.E.B. Sandberg et al., Journal of Medicinal Chemistry. Vol. 25, p. 1009 (1982)), as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, in rheumatic diseases such as fibrositis, and in gastrointestinal disorders and diseases of the GI tract, such as ulcerative colitis and Crohn's disease, etc. (see D. Regoli in "Trends in Cluster Headache,” edited by F. Sicuteri et al. , Elsevier Scientific Publishers, Amsterdam, 1987, pp. 85-95).
  • the present invention relates to a process fo preparing a compound of the formula
  • R 1 is aryl selected from indanyl, phenyl an naphthyl; heteroaryl selected from thienyl, furyl, pyridy and quinolyl; and cycloalkyl having 3 to 7 carbon atoms wherein one of said carbon atoms may optionally be replace by nitrogen, oxygen or sulfur; wherein each of said aryl an heteroaryl groups may optionally be substituted with one o more substituents, and said (C 3 -C 7 ) cycloalkyl may optionall be substituted with one or two substituents, sai substituents being independently selected from chloro, fluoro, bromo, iodo, nitro, alkyl optionall substituted from one to three fluoro groups, (C J -C JO ) alkox optionally substituted with from one to three fluoro groups,
  • R ** is defined as above, with either (a) a compound o O the formula R'CX, wherein R 1 is defined as above and X is leaving group (e.g., chloro, bromo, iodo or i idazole) , followed by treatment of the resulting amide with a reducin agent, (b) a compound of the formula R'CHO, wherein R 1 i defined as above, in the presence of a reducing agent, o
  • halo refers to chloro, bromo, fluoro or iodo.
  • the compounds of formula I have chiral centers an therefore exist in different enantiomeric forms.
  • Formula I includes all optical isomers of suc compounds, and mixtures thereof.
  • the present invention also relates to a process fo preparing a compound of the formula I, as depicted above, wherein R 1 and R 2 are defined as above, comprising reactin a compound of the formula IV, as depicted above, wherein R is defined as above, with a compound, of the formula R ⁇ HO, wherein R 1 is defined above, in the presence of a dryin agent or using an apparatus designed to remov azeotropically the water generated, to produce an i ine o the formula
  • R 1 and R 2 are defined as above, and then reacting the imine with a reducing agent to form a compound of the formula I, as depicted above, wherein R 1 and R 2 are defined as above.
  • the present invention also relates to a process for preparing a compound of the formula I, as depicted above, wherein R 1 and R 2 are defined as above, comprising reducing a compound of the formula
  • This invention also relates to a process for preparing a compound of the formula I, as depicted above, wherein R 1 and R 2 are defined as above, comprising reacting a compound of the formula
  • R 2 and X are defined as above.
  • reaction of a compound of the formula IV with compound of the formula R ⁇ HO to produce a compound of th formula I is typically carried out in the presence of reducing agent such as sodium cyanoborohydride, sodiu triacetoxyborohydride, sodium borohydride, hydrogen and metal catalyst, zinc and hydrochloric acid, or formic aci at a temperature from about -60°C to about 50°C.
  • reducing agent such as sodium cyanoborohydride, sodiu triacetoxyborohydride, sodium borohydride, hydrogen and metal catalyst, zinc and hydrochloric acid, or formic aci at a temperature from about -60°C to about 50°C.
  • Suitabl reaction inert solvents for this reaction include lowe alcohols (e.g., methanol, ethanol and isopropanol), aceti acid and tetrahydrofuran (THF) .
  • the solvent i acetic acid is about 25°C
  • the reducin agent is sodium triacetoxyborohydride. This reactio proceeds to give material in which the addition of the CH 2 R sidechain occurs selectively at the 3-amino group, and th isomer of formula I is the only product isolated.
  • reaction of a compound of th formula IV with a compound of the formula R'CHO may b carried out in the presence of a drying agent or using a apparatus designed to remove azeotropically the wate generated, to produce an imine of the formula
  • the preparation of the imine is generall carried out in a reaction inert solvent such as benzene, xylene or toluene, preferably toluene, at a temperature fro about 25°C to about 110°C, preferably at about the reflu temperature of the solvent.
  • Suitable drying agents/solven systems include titanium tetrachloride/dichloromethan titanium isopropoxide/dichloromethane and molecula sieves/THF. Titanium tetrachloride/dichloromethane i preferred.
  • reaction of a compound of the formula IV with compound of the formula R'CH-jX is typically carried out in reaction inert solvent such as dichloromethane or THF, preferably dichloromethane, at a temperature from about 0° to about 60°C, preferably at about 25°C.
  • reaction inert solvent such as dichloromethane or THF, preferably dichloromethane
  • R*CX is typically carried out in a inert solvent such as tetrahydrofuran (THF) o dichloromethane at a temperature from about -20°C to abou 60 Q C, preferably in dichloromethane at about 0°C.
  • Reductio of the resulting amide is accomplished by treatment with reducing agent such as borane dimethylsulfide complex lithium aluminum hydride or diisobutylaluminum hydride in a inert solvent such as ethyl ether or THF.
  • the reactio temperature may range from about 0°C to about the reflu temperature of the solvent.
  • the reduction i accomplished using borane dimethylsulfide complex in THF a about 60°C.
  • Reduction of the pyridine of formula II to form th corresponding piperidine of formula IV is generall accomplished using either sodium in alcohol, lithiu aluminum hydride/aluminum trichloride, electrolyti reduction or hydrogen in the presence of a metal containin catalyst.
  • the reduction with sodium is generally conducte in a boiling alcohol, preferably butanol, at a temperatur from about 20°C to about the reflux temperature of th solvent, preferably at about 120°C.
  • the reduction wit lithium aluminum hydride/aluminum trichloride is usuall carried out in ether, THF or dimethoxyethane, preferabl ether, at a temperature from about 25°C to about 100°C, preferably at about room temperature.
  • the electrolyti reduction is conducted, preferably, at room temperature, but temperatures from about 10°C to about 60°C are also suitable.
  • Hydrogenation in the presence of a metal containing catalyst is the preferred method of reduction.
  • Suitable hydrogenation catalysts include palladium, platinum, nickel, platinum oxide and rhodium.
  • the preferred catalyst for hydrogenation is platinum on carbon.
  • the reaction temperature may range from about 10°C to about 50°C, with about 25°C being preferred.
  • the hydrogenation is generally carried out at a pressure from about 1.5 to about 4 atmospheres, preferably at about 3.0 atmospheres, in a suitable inert solvent such as acetic acid or a lower alcohol, preferably methanol, with about a stoichiometric quantity of hydrogen chloride present.
  • the compounds of formula III may be treated with a dissolving metal such as lithium or sodium in ammonia at a temperature from about -30°C to about -78°C, or with a formate salt in the presence of palladium or with cyclohexene in the presence of palladium.
  • a dissolving metal such as lithium or sodium in ammonia at a temperature from about -30°C to about -78°C
  • the compounds of formula III are treated with hydrogen in the presence of palladium on carbon in a mixture of methanol/ethanol in water or methanol/ethanol containing hydrochloric acid at a temperature of about 25°C.
  • the only products isolated are the desired compounds of the formula IV. No products derived from cleavage of the alternative benzylic position of the piperidine ring (i.e., the bond between the nitrogen at position 1 and the carbon at position 2) are observed.
  • R'CX, R'CHO and R'CH 2 X that are used in the above reactions are either commercially available or obtainable by carrying out standard transformation well known to those skilled i the art upon commercially available materials.
  • the resolution of a racemic mixture of a compound o the formula I to prepare the (+) enantiomer of such compoun is generally carried out using methanol, ethanol, o isopropanol, preferably isopropanol, as the organic reactio inert solvent.
  • the resolution is carried out b combining a racemic mixture of a compound of the formula and (R)-(-)-mandelic acid in isopropanol, and stirring th mixture to form an optically enriched mandelic acid sal precipitate.
  • the optically enriched precipitate is the recrystallized twice from isopropanol, after which th recrystallized precipitate is converted to the free base o the optically pure compound of formula I by partitioning i between dichloromethane and an aqueous base such as sodiu hydroxide, sodium bicarbonate or potassium bicarbonate preferably sodium hydroxide, or by stirring an alcoholi solution of the salt with a basic ion exchange resin.
  • Th free base which is dissolved in the methylene chloride, ca then be converted to the corresponding hydrochloric aci salt.
  • Isolation of the mandelate may be conducted a temperatures from about 0°C to about 40°C. About 25°C i preferred.
  • pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5. atmospheres are generally acceptable, and ambient pressure, i.e., about one atmosphere, is preferred as a matter o convenience.
  • the compounds of Formula I and their pharmaceutically acceptable salts exhibit substance P receptor antagonist activity and therefore are of value in the treatment and prevention of a wide variety of clinical conditions the treatment or prevention of which are effected or facilitated by a decrease in substance P mediated neurotransmission.
  • Such conditions include inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease) , anxiety, depression or dysthymic disorders, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrositis.
  • these compounds are readily adapted to therapeutic use as substance P receptor
  • the compounds of the formula I and the pharmaceutically acceptable salts thereof can be administered via either the oral, parenteral or topical routes.
  • these compounds are most desirably administered in dosages ranging from about 5.0 mg up to about 1500 mg per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen.
  • a dosage level that is in the range of about 0.07 mg to about 21 mg per kg of body weight per day is most desirably employed.
  • the following examples illustrate the methods a compounds of the present invention but do not limit it scope.
  • the starting materials used in th reaction of this invention are either commecially availabl or obtainable by carrying out standard transformation wel known to those skilled in the art upon commerciall available materials.
  • Table 1 below indicates how th aldehydes of the formula R ⁇ HO used in the examples were obtained.
  • the standard transformations used to prepar these aldehydes are identified by one or more lower cas letters in the column labelled "Reaction Sequence" in Tabl 1. The letters used to identify such transformations ar explained in the key following Table 1.
  • the hydrochloric acid extract were basified with 1 M aqueous sodium hydroxide an extracted with methylene chloride.
  • the methylene chlorid extracts were dried (sodium sulfate) and concentrated t obtain 528 mg of colorless oil.
  • the oil was dissolved i methylene chloride, and ether saturated with hydroge chloride was added to the solution.
  • the resulting whit solid was collected by filtration and stirred in isopropano at 60°C for 2 hours. Filtration afforded 414 mg of th title compound as its hydrochloride.
  • Additional materia 400 mg was obtained by extracting the initial basic laye with additional methylene chloride, drying (sodium sulfate and concentration.
  • Examples 4-23 and 25-81 were prepared from either (+)-(2S,3S)-3-amino-2-phenylpiperidine or the corresponding racemate by employing the appropriat aldehyde and using a procedure similar to that of Example 2.
  • EXAMPLE 24 (2S,3S)-3-Amino-2-phenylpiperidine
  • a bottle were placed 31 g of 10% palladium-carbon 50 L of water, 300 mL of methanol, 450 mL of ethanol, 20 of concentrated aqueous hydrochloric acid and 15 g (0.0 mole) of the hydrochloride salt of (2S,3S)-3-(2 methoxybenzyl)amino-2-phenylpiperdine.
  • the mixture wa shaken under hydrogen (40 p.s.i.) for 1 day and filtere through a pad of diatomaceous earth.
  • the pad was rinse with 2N aqueous hydrochloric acid (HCl) , water, ethanol an water and concentrated with a rotary evaporator. Water wa added to the residue and the mixture was made basic using 4 aqueous sodium hydroxide (NaOH) . The mixture was extracte with four portions of dichloromethane, and the extracts were dried over magnesium sulfate (MgS0 4 ) and concentrated t obtain 2.23 g of the title compound. The aqueous fractio was concentrated to dryness and triturated with chloroform. Concentration of the chloroform solution afforded a additional 4.15 g of title compound. The product obtaine in this manner had spectral properties identical to those of the product of Example 1.
  • Cis-3- (2 , 3-dimethoxybenzyl) amino-2 -phenylpiperidine M.p. 238-240°C (HCl salt) .
  • EXAMPLE 54 ( 2S , 3S) -3- ( 4-Amino-5-chloro-2-methoxybenzyl) amino-2- phenylpiperidine hydrochloride M.P. 200-203°C (dec) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nouveaux procédés de préparation stéréosélective de dérivés de pipéridine substituée répondant aux formules (IV) et (I), dans lesquelles R1 et R2 ont les mêmes notations que ci-dessous.
EP92905084A 1991-03-26 1992-01-14 Preparation stereoselective de piperidines substituees Ceased EP0581777A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67524491A 1991-03-26 1991-03-26
US675244 1991-03-26

Publications (1)

Publication Number Publication Date
EP0581777A1 true EP0581777A1 (fr) 1994-02-09

Family

ID=24709639

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92905084A Ceased EP0581777A1 (fr) 1991-03-26 1992-01-14 Preparation stereoselective de piperidines substituees

Country Status (26)

Country Link
US (1) US5686615A (fr)
EP (1) EP0581777A1 (fr)
JP (1) JPH0794440B2 (fr)
KR (1) KR0145432B1 (fr)
CN (1) CN1038932C (fr)
AU (1) AU647592B2 (fr)
BR (1) BR9205807A (fr)
CA (1) CA2106200C (fr)
CZ (3) CZ289960B6 (fr)
EG (1) EG19976A (fr)
FI (1) FI106199B (fr)
HU (1) HUT67276A (fr)
IE (1) IE920939A1 (fr)
IL (2) IL101328A (fr)
MX (1) MX9201315A (fr)
MY (1) MY110886A (fr)
NO (1) NO180484C (fr)
NZ (1) NZ242116A (fr)
PL (1) PL169993B1 (fr)
PT (1) PT100282A (fr)
RU (1) RU2105001C1 (fr)
SK (2) SK284185B6 (fr)
TW (1) TW213900B (fr)
WO (1) WO1992017449A1 (fr)
YU (1) YU48260B (fr)
ZA (1) ZA922164B (fr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
HU224443B1 (hu) * 1991-06-20 2005-09-28 Pfizer Inc. Fluor-alkoxi-benzaldehid-származékok
EP1082959A1 (fr) 1991-09-20 2001-03-14 Glaxo Group Limited Utilisation des NK1-antagonistes pour le traitement de la depression
ATE209186T1 (de) * 1992-05-18 2001-12-15 Pfizer Überbrückte azabicyclische derivate als substanz p antagonisten
CA2141051A1 (fr) * 1992-08-04 1994-02-17 Terry J. Rosen Derives de substitution d'heterocycles azotes
US5721255A (en) * 1992-08-19 1998-02-24 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
EP0675886B1 (fr) 1992-12-10 2000-07-05 Pfizer Inc. Heterocycles non aromatiques substitues par aminomethylene et leur utilisation comme antagonistes de substance p
US6369074B1 (en) * 1992-12-10 2002-04-09 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5294744A (en) * 1993-04-20 1994-03-15 Pfizer Inc. Formylation process for aromatic aldehydes
DK0700384T3 (da) * 1993-05-28 1997-12-08 Pfizer fremgangsmåde til fremstilling og opløsning af 2-phenyl-3-aminopiperidin
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (fr) * 1993-11-17 1995-10-11 Pfizer Antagonistes de la substance P pour le traitement et la prévention de l'erythème solaire.
EP0659409A3 (fr) * 1993-11-23 1995-08-09 Pfizer Antagonistes de la substance P pour l'inhibition de l'angiogénése.
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
KR19980703354A (ko) * 1995-03-27 1998-10-15 나카토미히로타카 피페리딘 유도체
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
DE69623580T2 (de) * 1995-12-21 2003-01-09 Pfizer Inc., New York 3-((5-Substituierte Benzyl)Amino)-2-Phenylpiperidine als Substance-P-Antagonisten
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
EP0977572A1 (fr) * 1997-04-24 2000-02-09 Merck Sharp & Dohme Ltd. Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires
CA2298777A1 (fr) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 pour le traitement d'une manie
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
WO1999007375A1 (fr) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 pour le traitement de troubles du comportement agressifs
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
EP1095939B1 (fr) * 1999-10-18 2004-01-07 Pfizer Products Inc. Procédé de préparation d'éthers cycliques contenant pipéridinylaminométhyl-trifluorométhyl
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2001032625A1 (fr) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Tetrahydroisoquinolines a substitution aryle et heteroaryle et utilisation de ces composes pour bloquer le recaptage de norepinephrine, de dopamine et de serotonine
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
KR20030036834A (ko) * 2000-09-26 2003-05-09 다나베 세이야꾸 가부시키가이샤 5-페닐벤질아민 화합물, 그의 제법 및 그의 합성 중간체
AU2001292320A1 (en) * 2000-10-02 2002-04-15 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
CN101353321A (zh) * 2002-11-21 2009-01-28 辉瑞产品公司 3-氨基-哌啶衍生物及其制备方法
EP1753722A2 (fr) * 2004-05-21 2007-02-21 Pfizer Products Inc. Metabolites de (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
KR101269568B1 (ko) * 2005-07-04 2013-06-04 자난 사이텍 컴퍼니 리미티드 루테늄 착물 리간드, 루테늄 착물, 고정 루테늄 착물 촉매및 그의 제조방법과 용도
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
WO2007015588A1 (fr) * 2005-08-04 2007-02-08 Takeda Pharmaceutical Company Limited Dérivé de pipéridine comme antagoniste récepteur de la tachykinine
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
WO2010132487A1 (fr) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (fr) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
EP2699567A1 (fr) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (fr) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs d'hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
CN103204768A (zh) * 2013-03-12 2013-07-17 西北大学 一种对羟基苯甲醛的合成方法
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020019247A1 (fr) * 2018-07-26 2020-01-30 Xw Laboratories, Inc. Composés en tant qu'antagonistes du récepteur de la neurokinine -1 et leurs utilisations
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
EP3833668B1 (fr) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2355659A (en) * 1939-12-15 1944-08-15 Hoffmann La Roche Piperidine derivatives and process for the manufacture of the same
US4267318A (en) * 1979-09-12 1981-05-12 G. D. Searle & Co. 1-(Diarylmethyl)-4-piperidinamine and derivatives thereof
US4680283A (en) * 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
WO1990005525A1 (fr) * 1988-11-23 1990-05-31 Pfizer Inc. Derives de quinuclidine en tant qu'antagonsites de substance p
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
JPH0794439B2 (ja) * 1990-05-31 1995-10-11 フアイザー・インコーポレイテツド 置換ピペリジンの製造法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9217449A1 *

Also Published As

Publication number Publication date
CA2106200C (fr) 1996-11-19
PL169993B1 (pl) 1996-09-30
YU29892A (sh) 1994-12-28
US5686615A (en) 1997-11-11
CZ293955B6 (cs) 2004-08-18
SK284185B6 (sk) 2004-10-05
IL137021A0 (en) 2001-06-14
JPH06502182A (ja) 1994-03-10
BR9205807A (pt) 1994-06-28
YU48260B (sh) 1997-09-30
JPH0794440B2 (ja) 1995-10-11
SK367292A3 (en) 2000-12-11
CZ367292A3 (en) 1993-09-15
ZA922164B (en) 1993-09-27
WO1992017449A1 (fr) 1992-10-15
HUT67276A (en) 1995-03-28
CZ289960B6 (cs) 2002-05-15
IE920939A1 (en) 1992-10-07
HU9302709D0 (en) 1993-12-28
CN1065264A (zh) 1992-10-14
AU1244892A (en) 1992-11-02
KR0145432B1 (ko) 1998-07-15
NO180484C (no) 1997-04-30
MY110886A (en) 1999-06-30
NO933413L (no) 1993-09-24
NO933413D0 (no) 1993-09-24
TW213900B (fr) 1993-10-01
CN1038932C (zh) 1998-07-01
AU647592B2 (en) 1994-03-24
EG19976A (en) 1997-01-30
NO180484B (no) 1997-01-20
PT100282A (pt) 1993-06-30
MX9201315A (es) 1992-10-01
FI106199B (fi) 2000-12-15
CA2106200A1 (fr) 1992-09-27
SK284565B6 (sk) 2005-06-02
FI934186L (fi) 1993-09-24
FI934186A0 (fi) 1993-09-24
IL101328A0 (en) 1992-11-15
RU2105001C1 (ru) 1998-02-20
NZ242116A (en) 1995-10-26
CZ293954B6 (cs) 2004-08-18
IL101328A (en) 2000-10-31

Similar Documents

Publication Publication Date Title
WO1992017449A1 (fr) Preparation stereoselective de piperidines substituees
CZ390892A3 (en) Fluoroalkoxybenzylamide derivatives of nitrogen-containing heterocycles
EP0613458A1 (fr) Derives d'ethylenediamine acycliques utilises comme antagonistes du recepteur de substance p
AU648558B2 (en) Preparation of substituted piperidines
EP0700384B1 (fr) Procede de preparation et de resolution de 2-phenyl-3-aminopiperidine
PL173659B1 (pl) Sposób wytwarzania nowych pochodnych piperydyny
RU2232753C2 (ru) 4-замещенные пиперидины, фармацевтическая композиция на их основе и способ лечения заболеваний центральной нервной системы
JP2009529534A (ja) 中枢神経系活動に用いられるホモトロパン

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930917

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960722

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19970330